Expectations and Beliefs of Transgender People Regarding Hormonal Treatment

July 23, 2022 updated by: EVA FEIGERLOVA, Central Hospital, Nancy, France

Hormonal treatment of gender dysphoria can have repercussions on metabolism, cardiovascular system and fertility and represents à potential oncological risk. According to the recommendations of the Endocrine society. Therefore, initial assessment and follow-up visits are necessary and must be carried out to avoid the apparition of potentially undesirable effects.

Study Overview

Status

Recruiting

Conditions

Transgenderism

Intervention / Treatment

Other: no intervention

Study Type

Observational

Enrollment (Anticipated)

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

France
- - Nancy, France
    - Recruiting
    - CHRU de Nancy
    - Contact:
      
      Eva Feigerlova
      
      Phone Number: 33 (0)3 83 15 34 12
      
      Email: e.feigerlova@chru-nancy.Fr

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

adults with gender dysphoria and parent of adolescent/child presenting gender dysphoria, who are followed un the university hospital of Nancy

Description

Inclusion Criteria:

being a parent of adolescent/child presenting Gender dysphoria
adult subject (age > 18 years) presenting Gender dysphoria

non-inclusion criteria

Severe, uncontrolled psychiatric or somatic illness
Chronic alcoholism
Substance abuse
Refusal or linguistic, physical or psychological incapacity to participate in the study
Ongoing pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Describe expectations and beliefs of transgener people about hormonal therapy Time Frame: 12 months	qualitative analysis of qualitative data from collective discussions (focus groups)	12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Central Hospital, Nancy, France

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

February 2, 2022

Primary Completion (ANTICIPATED)

November 1, 2022

Study Completion (ANTICIPATED)

January 1, 2023

Study Registration Dates

First Submitted

July 22, 2022

First Submitted That Met QC Criteria

July 23, 2022

First Posted (ACTUAL)

July 26, 2022

Study Record Updates

Last Update Posted (ACTUAL)